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MUC1 ectodomain 
is a flagellin‑targeting decoy 
receptor and biomarker operative 
during Pseudomonas aeruginosa 
lung infection
Avelino C. Verceles1,2, Pavan Bhat1, Zain Nagaria1, Destiny Martin1, Harsh Patel1, 
Afua Ntem‑Mensah1, Sang W. Hyun1,2, Andrea Hahn3,4, Jean Jeudy5, Alan S. Cross1,6, 
Erik P. Lillehoj7* & Simeon E. Goldblum1,2
We previously reported that flagellin‑expressing Pseudomonas aeruginosa (Pa) provokes NEU1 
sialidase‑mediated MUC1 ectodomain (MUC1‑ED) desialylation and MUC1‑ED shedding from 
murine lungs in vivo. Here, we asked whether Pa in the lungs of patients with ventilator‑associated 
pneumonia might also increase MUC1‑ED shedding. The levels of MUC1‑ED and Pa‑expressed 
flagellin were dramatically elevated in bronchoalveolar lavage fluid (BALF) harvested from 
Pa‑infected patients, and each flagellin level, in turn, predicted MUC1‑ED shedding in the same 
patient. Desialylated MUC1‑ED was only detected in BALF of Pa‑infected patients. Clinical Pa strains 
increased MUC1‑ED shedding from cultured human alveolar epithelia, and FlaA and FlaB flagellin‑
expressing strains provoked comparable levels of MUC1‑ED shedding. A flagellin‑deficient isogenic 
mutant generated dramatically reduced MUC1‑ED shedding compared with the flagellin‑expressing 
wild‑type strain, and purified FlaA and FlaB recapitulated the effect of intact bacteria. Pa:MUC1‑ED 
complexes were detected in the supernatants of alveolar epithelia exposed to wild‑type Pa, but not to 
the flagellin‑deficient Pa strain. Finally, human recombinant MUC1‑ED dose‑dependently disrupted 
multiple flagellin‑driven processes, including Pa motility, Pa biofilm formation, and Pa adhesion to 
human alveolar epithelia, while enhancing human neutrophil‑mediated Pa phagocytosis. Therefore, 
shed desialylated MUC1‑ED functions as a novel flagellin‑targeting, Pa‑responsive decoy receptor that 
participates in the host response to Pa at the airway epithelial surface.
Ventilator-associated pneumonia (VAP) is defined by the appearance of a new pulmonary infiltrate of infectious 
origin occurring more than 48 h after endotracheal (ET)  intubation1. This common nosocomial infection occurs 
in approximately 10% of ventilated  patients2. Although the reported incidences per 1000 ventilator days has 
decreased from 3.1 to 0.9 in medical intensive care units (ICUs), and from 5.2 to 2.0 in surgical ICUs, attributable 
morbidity and mortality remain relatively  high3,4. All-cause mortality associated with VAP is reportedly 20% 
to 50%, while attributable mortality is estimated to be 13%1,5. VAP is associated with prolonged hospitalization 
and increased cost. In risk-matched patients either with or without VAP, the presence of pneumonia added an 
average of US $40,000 to hospital costs and 10 days to total time on mechanical ventilation, ICU stay, and/or 
overall  hospitalization6. Prolonged intubation is a primary driver of infection, with risk of VAP increasing by 2% 
per day, starting in the second week post-intubation7. Other modifiable risk factors include the use of antacids, 
supine position, and receipt of enteral nutrition. Non-modifiable risk factors include coma, age greater than 
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60 years, head trauma, chronic obstructive pulmonary disease, and male gender. Intervention-related factors, 
such as neurologic or thoracic surgery and reintubation, contribute to VAP as  well7.
For the diagnosis of VAP, the findings of a new pulmonary infiltrate in the setting of fever, purulent sputum, 
leukocytosis, and hypoxemia provide a reported sensitivity of 69% and specificity of 75%1. This translates to 
positive and negative likelihood ratios of 2.5 and 0.06,  respectively8. However, no known combination of signs 
and symptoms provides a definitive diagnosis. Addition of noninvasive, semiquantitative sputum cultures by 
ET aspirate, can help with organism- and susceptibility-directed  therapy1. In these critically-ill patients, the 
absence of a reliable diagnostic approach can lead to over-diagnosis and overuse of broad-spectrum antibiotics, 
encouraging the development of multidrug-resistant (MDR)  pathogens9.
The predominant mechanisms underlying VAP pathogenesis include microaspiration of oropharyngeal secre-
tions and bacterial biofilm formation within the ET  tube10. Whether pneumonia ensues is dictated by organism 
virulence factors, inoculum size, and the host immune  response11. In the ventilated patient, the presence of an ET 
tube impairs the cough reflex, decreasing the ability to expel pathogens. Over time, the ET tube luminal surface 
serves as a nidus for bacterial colonization and biofilm formation that can be impregnable to antibiotics. These 
bacteria can then be introduced into the lower respiratory tract by positive ventilatory  pressure10.
Pseudomonas aeruginosa (Pa), a flagellated, Gram-negative bacillus, is a leading pathogen implicated in VAP, 
with a reported frequency approaching 25%12. Nonventilated patients who are debilitated with burns, neutrope-
nia, or cystic fibrosis are also at increased risk of Pa  acquisition13. Pa commonly colonizes healthcare workers, 
and in one study, was recovered from 22% of hospital  rooms8. Hospital reservoirs include showers, cleaning 
equipment, bronchoscopes, endoscopes and respiratory therapy  equipment13. Antibacterial-susceptible strains 
that colonize patients can become MDR through ubiquitous antibiotic use and selective pressure.
The first host barrier with which Pa interacts in the airways is the mucus blanket which covers the 
 epithelium14,15. This mucus blanket made up of two distinct yet interacting layers, a highly viscous gel layer 
overlying a periciliary liquid layer. Members of the mucin family comprise the major protein component of 
mucus and are divided into secreted and cell-associated mucins. Of the 5 major mucins that have been detected 
in the lung, two are secreted, MUC5AC and MUC5B, and three are cell-tethered, MUC1, MUC4, and MUC16. 
MUC1 is comprised of an  NH2-terminal MUC1 ectodomain (MUC1-ED) coupled to a COOH-terminal MUC1 
cytoplasmic domain (MUC1-CD)14,15. The MUC1-ED contains a variable number of highly sialylated, 20-amino 
acid (aa) tandem repeats distal to a juxtamembranous glycine-serine protease recognition site. The proline-
rich MUC1-ED exhibits an extended, rod-like conformation that protrudes higher above the EC surface than 
other membrane-associated  proteins16. Here, the MUC1-ED is strategically positioned to interact with flagellin-
expressing Pa in the airway lumen. The MUC1-ED is up to 90% carbohydrate, almost entirely through more than 
500 predicted O-linked glycosylation sites within its tandem  repeats17. The relatively short, 72-aa MUC1-CD 
contains multiple binding sites for cytosolic signaling  molecules18–20.
We had previously established that Pa-expressed flagellin engages the MUC1-ED expressed on the surface 
of airway epithelial cells (ECs)21 (Fig. 1). We found that this receptor-ligand interaction recruits the eukaryotic 
Figure 1.  Pa-expressed flagellin provokes NEU1-mediated MUC1-ED desialylation to generate a flagellin-
targeting MUC1-ED decoy receptor. The Pa flagellin subunit engages cell-associated MUC1-ED (step 1), 
leading to recruitment of a preformed pool of intracellular NEU1, together with its chaperone protein, PPCA, 
to MUC1-ED (step 2). NEU1 desialylates the MUC1-ED (step 3), to increase its adhesiveness for Pa (step 4) and 
unmask its glycine-serine (Gly-Ser) protease recognition site (step 5), permitting sheddase-mediated MUC1-ED 
release from the airway EC surface (step 6). Shed, desialylated MUC1-ED in the airway lumen acts as a soluble 
decoy receptor that reduces Pa motility, competitively inhibits Pa adhesion to cell-associated MUC1-ED and 
subsequent invasion of airway epithelia, protects against Pa biofilm formation, and enhances Pa phagocytosis by 
host PMNs (step 7).
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sialidase, NEU1, together with its chaperone protein, protective protein/cathepsin A (PPCA), to surface-
expressed  MUC121,22. Further, we found that NEU1 desialylates the MUC1-ED to unmask cryptic binding sites 
for flagellin-expressing  Pa21,23 (Fig. 1). In contrast, NEU1-mediated MUC1-ED desialylation did not increase its 
adhesiveness for a flagellin-deficient, isogenic Pa  mutant21. While NEU1 overexpression in MUC1-expressing 
human embryonic kidney (HEK)293 cells enhanced their adhesiveness for wild-type Pa, NEU1 overexpression 
in Toll-like receptor (TLR)5-expressing HEK293 cells did  not21. Although NEUs are well established virulence 
factors for multiple bacterial  pathogens24, this is the only case, to our knowledge, where a prokaryote hijacks 
a host sialidase to influence its pathogenicity. At the same time, we also found that NEU1-mediated MUC1-
ED desialylation uncovers a juxtramembranous protease recognition site, permitting MUC1-ED cleavage by 
endogenous sheddases and release from the EC  surface21,25–27 (Fig. 1). More specifically, NEU1 overexpression 
in HEK293 cells expressing a MUC1-ED S317A mutant, containing a serine-to-alanine substitution within 
the glycine-serine protease recognition site, displayed no MUC1-ED  shedding22. Shed, desialylated MUC1-
ED in the airway lumen retains its ability to bind to flagellin-expressing Pa, thereby acting as a soluble decoy 
receptor that reduces Pa motility and competitively inhibits Pa adhesion to cell-associated MUC1-ED21,22, both 
reducing Pa invasion of underlying  tissues22. In fact, in a mouse model of Pa pneumonia, co-administration of 
the MUC1-ED decoy receptor with a lethal challenge of Pa diminished lung bacterial burden, lung cytokine 
production, and pulmonary leukostasis, and increased 5-day survival from 0 to 77%, indicating that the shed 
MUC1-ED constitutes a protective component of the host response to  Pa22 (Fig. 1). In the current studies, we 
sought to extend our prior findings in the mouse model to an in vivo human setting. We asked whether the shed 
MUC1-ED levels might be elevated in BALF of Pa-infected patients, as an indirect but specific measure of NEU1 
catalytic  activity21,23. Further, we tested human recombinant MUC1-ED for its ability to influence Pa adhesion 
to alveolar epithelia, Pa motility, Pa biofilm production, Pa-stimulated interleukin-8 (IL-8) production, and 
neutrophil-mediated Pa phagocytosis.
Results
MUC1‑ED levels in bronchoalveolar lavage fluid (BALF) from Pa‑infected patients. We previ-
ously reported that Pa increases MUC1-ED shedding using an in vivo mouse model of Pa  pneumonia22. We asked 
whether MUC1-ED levels also might be increased in BALF from patients with Pa airway infection. Between 12 
June 2013 and 20 February 2020, BALF was collected from 61 patients undergoing mechanical ventilation and 
clinically diagnosed with VAP in three separate units at the University of Maryland Medical Center (Baltimore, 
MD). Of these 61 patients, the BALF of 13 (21.3%) were culture-positive for Pa, 32 (52.5%) culture-positive 
for other microorganisms, 6 of which were polymicrobial, and 16 (26.2%) culture-negative (Table 1). Power 
analysis indicated that this study is 100% powered with these sample sizes to detect different BALF MUC1-ED 
levels in Pa-positive (n = 13) vs. Pa-negative (n = 48) patients. Pa-infected VAP patients were more likely to have 
been admitted to the long-term Comprehensive Pulmonary Rehabilitation Unit (CPRU) (61.5% vs. 12.5%), and 
experienced fewer ventilator-free days (8.2 vs. 18.7 days), compared with Pa-negative patients (Table 1). Interest-
ingly, Pa-infected VAP patients were less likely to have been admitted to the acute care Medical Intensive Care 
Table 1.  Patient characteristics. a Aspergillus spp. (n = 1), Candida spp. (n = 2), Candida albicans (n = 5), 
Candida parapsilosis (n = 1), Enterococcus spp. (n = 4), Escherichia coli (n = 1), Klebsiella oxytoca (n = 1), 
Klebsiella pneumoniae (n = 1), Lactobacillus spp. (n = 1), Mycobacterium chelonae (n = 1), normal respiratory 
flora (n = 4), Proteus mirabilis (n = 1), Rothia spp. (n = 1), Staphylococcus spp. (n = 3), Staphylococcus aureus 
(n = 1), Streptococcus spp. (n = 6), Streptococcus pyogenes (n = 1).
VAP Patients P. aeruginosa (n = 13) Other microorganisms (n = 32)a or culture-negative (n = 16) p Value
Age in years, mean S.D 61.8 ± 9.8 58.6 ± 12.7 0.42
BMI, mean S.D 32.1 ± 11.9 31.3 ± 10.6 0.81
Ventilator-free days, mean S.D 8.2 ± 11.3 18.7 ± 10.0 0.002
APACHE II Score, mean ± S.D 17.7 ± 7.0 18.6 ± 8.7 0.72
Race, n
White 7 (53.8%) 27 (56.2%) 0.88
African American 6 (46.2%) 18 (37.5%) 0.58
Other 0 (0.0%) 3 (6.3%) 0.36
Gender, n
Male 4 (30.8%) 24 (50.0%) 0.22
Female 9 (69.2%) 24 (50.0%) 0.22
ICU Locationm, n
Acute Care MICU 5 (38.5%) 39 (81.2%) 0.002
Acute Care CCRU 0 (0.0%) 3 (6.3%) 0.36
Long-Term CPRU 8 (61.5%) 6 (12.5%)  < 0.001
Antibiotics, n 13 (100%) 46 (96.0%) 0.45
Anti-Pseudomonal Antibiotics 13 (100%) 39 (81.3%) 0.11
Chest X-ray Abnormality, n 13 (100%) 46 (96.0%) 0.45
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Unit (MICU) compared with Pa-negative patients (38.5% vs. 81.2%). None of the other clinical/demographic 
parameters measured were different between Pa-infected patients and Pa-negative patients.
MUC1-ED levels in these 61 BALF samples were quantified by enzyme-linked immunosorbent assay (ELISA) 
and normalized to total BALF protein. Mean ± S.E. normalized MUC1-ED levels were 4.01 ± 0.19 µg/mg BALF 
protein (range, 2.87 µg/mg to 5.34 µg/mg) in the BALF from the 13 Pa-infected VAP patients compared with 
0.71 ± 0.05 µg/mg (range, 0.05 µg/mg to 1.55 µg/mg) in the BALF from the 32 patients infected with other micro-
organisms and 0.52 ± 0.08 µg/mg (range, 0.17 µg/mg to 1.24 µg/mg) in the BALF from the 16 culture-negative 
patients (Fig. 2A,B). Therefore, the mean normalized MUC1-ED level in Pa-infected VAP patients was 5.6-fold 
greater than that measured in patients infected with other microorganisms, and 7.7-fold greater compared with 
culture-negative patients. These combined data suggest that elevated BALF levels of MUC1-ED might provide 
a diagnostic biomarker for Pa lung infection. We asked whether MUC1-ED levels in BALF of Pa-infected VAP 
patients might correlate with Acute Physiology and Chronic Health Evaluation (APACHE) II scores as a predic-
tor of disease severity. In 11 patients where APACHE II scores were available, MUC1-ED levels did not correlate 
with APACHE II values (Supplemental Fig. 1).
Since NEU1-mediated MUC1-ED desialylation is required for its proteolytic release and  shedding22, we next 
asked whether MUC1-ED in BALF from Pa-infected patients was desialylated. MUC1-ED immunoblotting of 
BALF proteins bound to the lectin, peanut agglutinin (PNA), which binds to subterminal galactose residues only 
after removal of terminal sialic acid, was used to address this question. First, we validated the specificity of the 
PNA lectin. As anticipated, PNA recognized asialofetuin, but not sialylated fetuin (Fig. 2C). MUC1-ED in the 
BALF of Pa-infected VAP patients was desialylated, while desialylated MUC1-ED in the BALF from Pa-negative 
patients was not detected (Fig. 2D). Similarly, total shed MUC1-ED was detected in the BALF from Pa-infected 
VAP patients, but not in the BALF from Pa-negative patients (Fig. 2E). The total MUC1-ED concentrations in 
the four selected samples from the Pa-positive group were comparable, as were the MUC1-ED levels in the four 
selected Pa-negative samples (Fig. 2E). Of note, although low levels of MUC1-ED were seen by ELISA in BALF 
harvested from the two Pa-negative patient groups (Fig. 2A,B), desialylated MUC1-ED could not be detected in 
Pa-negative patients either by the combined PNA enrichment/MUC1-ED immunoblotting protocol (Fig. 2D, 
lanes 1–4) or the immunoblotting-only protocol (Fig. 2E, lanes 1–4). It is conceivable that the relatively higher 
sensitivity of the ELISA procedure, compared with the PNA/immunoblotting or immunoblotting-only protocols, 
allows detection of very low levels of MUC1-ED by the former and not the latter.
MUC1-ED levels were also quantified in tracheal aspirate (TA)s and BALFs simultaneously collected from a 
subset of VAP patients (n = 15), including 2 patients infected with Pa, 6 patients infected with other microorgan-
isms, and 7 culture-negative patients. No correlation was observed between MUC1-ED levels in the paired BALF 
and TA samples (Supplemental Fig. 2). Therefore, the MUC1-ED levels in the more easily obtained TA samples 
did not reflect BALF levels. However, due to the small sample size for TAs obtained from patients who cultured 
positive for Pa, whether a correlation exists could not be definitively excluded.
MUC1‑ED shedding by Pa‑derived flagellin. MUC1-ED levels are increased in the BALF of mice chal-
lenged with either flagellin-expressing Pa or purified Pa-derived  flagellin22 and in BALF from VAP patients 
infected with Pa (Fig. 2A,B). We asked whether Pa-derived flagellin might be responsible for MUC1-ED shed-
ding, in vitro. First, we used an in vitro bacterial motility assay to establish flagella expression in selected micro-
organisms, including wild-type (WT)-PAK, Stenotrophomonas maltophilia, Legionella pneumophila, and Salmo-
nella enterica serovar Typhimurium. A nonmotile PAK/fliC¯ flagellin-deficient, isogenic mutant strain was used 
as a negative control. With the exception of the PAK/fliC¯ strain, all microorganisms were motile (Fig. 3A). We 
next established the time requirements for WT-PAK-provoked increases in MUC1-ED shedding from in vitro 
cultures of A549 human alveolar epithelial cells (ECs) (Fig.  3B). At times ≥ 2 h, shed MUC1-ED levels were 
increased over time, with maximal levels at 24 h. Over the same time period, the PAK/fliC¯ mutant strain only 
induced minimal MUC1-ED shedding at later time points that did not achieve statistical significance compared 
with the phosphate-buffered saline (PBS) vehicle control. Stimulation of in vitro cultures of A549 ECs with either 
of two Pa laboratory strains, PA01 or PAK, dramatically increased MUC1-ED levels in cell culture supernatants 
compared with the PBS control (Fig. 3C). A549 EC stimulation with the PAK/fliC¯ flagellin-deficient strain was 
associated with dramatically reduced MUC1-ED shedding compared with that provoked by flagellin-expressing 
Figure 2.  MUC1-ED levels are increased in BALF from P. aeruginosa-infected VAP patients. (A) MUC1-ED 
levels in BALF from noninfected patients (n = 16), patients infected with microorganisms other than Pa (n = 32), 
or Pa-infected patients (n = 13) were quantified by ELISA and normalized to total BALF protein. The dashed line 
represents an arbitrary cut-off value to differentiate BALF MUC1-ED levels in Pa-infected patients from patients 
infected with microorganisms other than Pa or noninfected patients. Bars represent mean ± S.E. values (n = 3). 
Open circles represent individual values. (B) Box and whisker plots of the data in (A). *, increased MUC1-ED 
levels compared with noninfected patients or patients infected with microorganisms other than Pa at p < 0.05. 
(C) Fetuin and asialofetuin (1.0 µg) were processed for PNA lectin blotting (lanes 1, 2) as controls to validate 
PNA specificity. (D, E) Equal protein aliquots (100 µg) of BALF from noninfected patients or patients infected 
with microorganisms other than Pa (lanes 1–4), or Pa-infected patients (lanes 5–8) were (D) incubated with 
PNA-agarose and the PNA-binding proteins processed for MUC1-ED immunoblotting or (E) directly processed 
for MUC1-ED immunoblotting. MUC1-ED concentrations by ELISA are indicated under each lane in (E). 
Molecular weights in kDa are indicated on the right. Each arrow indicates the > 250 kDa MUC1-ED band of 
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WT-PAK. However, the PAK/fliC¯ strain still increased MUC1-ED shedding compared with the PBS control, 
indicating that Pa constituent(s) other than flagellin might also be operative. Purified Pa lipopolysaccharide 
(LPS),  Pam3Cys-Ser-(Lys)4 as a bacterial lipoprotein mimetic, and CpG oligodeoxynucleotide (ODN) 1826 as a 
bacterial DNA mimetic, each failed to increase MUC1-ED shedding (Fig. 3C). Whether other untested bacterial 
components contribute to Pa flagellin-provoked MUC1-ED shedding remains unclear. Five clinical strains of Pa 
isolated from blood cultures of pneumonia patients stimulated MUC1-ED shedding comparable with the PA01 
and PAK laboratory strains. A549 cells were incubated with two flagellated and four nonflagellated respiratory 
pathogens. Of the two flagellated bacteria, S. maltophilia increased MUC1-ED shedding, whereas L. pneumoph-
ila did not (Fig. 3C). None of the four nonflagellated bacteria, including Streptococcus pneumoniae, Haemophilus 
influenzae, Staphylococcus aureus, or Klebsiella pneumoniae, increased MUC1-ED shedding (Fig. 3C). Each Pa 
strain expresses one of two types of flagellin, a-type (FlaA) or b-type (FlaB)28. Purified FlaA flagellin isolated 
from the PAK strain, and Escherichia coli-expressed recombinant (r)FlaA and rFlaB, cloned from PAK and PA01, 
respectively, stimulated MUC1-ED shedding (Fig. 3C). Since Pa-expressed flagellin clearly provoked MUC1-
ED shedding, we asked whether the established pattern recognition receptor for bacterial flagellins,  TLR529, 
might be operative. To address this issue, we introduced a well-recognized TLR5 agonist, S. enterica serovar 
Typhimurium (STm)-derived  flagellin30. STm-derived flagellin provoked far less MUC1-ED shedding than did 
Pa-derived flagellin, excluding participation of TLR5 (Fig. 3C). In other experiments, A549 ECs were stimu-
lated with increasing inocula of WT-PAK or PAK/fliC¯, and after 24 h, cell culture supernatants collected, and 
MUC1-ED levels assayed and normalized to total EC protein. WT-PAK inocula ≥ 1.0 ×  104 colony forming units 
(CFUs) dose-dependently increased MUC1-ED shedding compared with an identical inoculum of PAK/fliC¯ 
(Fig. 3D). Therefore, flagellin-expressing Pa and S. maltophilia, as well as Pa-derived flagellin itself, each specifi-
cally induces MUC1-ED shedding from the surface of cultured human alveolar epithelia, in vitro.
Formation of complexes comprised of flagellin‑expressing Pa and the shed MUC1‑ED decoy 
receptor. Since NEU1-mediated MUC1-ED desialylation both renders the ED hyperadhesive for  Pa21 and 
unmasks its protease recognition site, permitting its proteolytic  release21,22, we asked whether shed MUC1-ED 
might bind to flagellin-expressing Pa. WT-PAK and the PAK/fliC¯ strain each were co-cultured for 24 h with 
A549 cells, the supernatants collected and centrifuged to collect the bacteria. The collected Pa were lysed and the 
lysates processed for MUC1-ED immunoblotting (Fig. 3E). The WT-PAK was detected in Pa:MUC1-ED com-
plexes, whereas the PAK/fliC¯ strain was not. Whether these Pa:MUC1-ED complexes form with cell-tethered 
MUC1-ED at the airway epithelial cell surface and are then released, and/or form with already shed MUC1-ED 
unoccupied by Pa, is unclear.
Pa‑derived flagellin is present in the BALF of Pa‑infected VAP patients. Flagellin-expressing Pa 
stimulates MUC1-ED shedding in vitro (Fig. 3), and MUC1-ED levels are increased in the BALF of mice with Pa 
lung  infection22 and Pa-infected patients with VAP (Fig. 2A,B). We asked whether Pa flagellin could be detected 
in the BALF of Pa-infected VAP patients. FlaA and FlaB flagellin levels were quantified by ELISA and normal-
ized to total BALF protein. The mean ± S.E. normalized FlaA level was 131.5 ± 9.1 ng/mg BALF protein (range, 
91.6 to 154.9 ng/mg) in 7 of 13 VAP patients infected with FlaA-expressing Pa (Fig. 4A,B). The mean ± S.E. 
normalized FlaB level was 139.7 ± 6.8 ng/mg (range, 112.0 to 163.4 ng/mg) in 6 of 13 VAP patients infected 
with FlaB-expressing Pa (Fig. 4A,B). Only one flagellin type, either FlaA or FlaB, was present in each of the 13 
patient BALFs, suggesting that only one Pa strain was responsible for each patient’s infection, but not absolutely 
Figure 3.  Flagellin-expressing Pa induces MUC1-ED shedding in vitro. (A) Bacterial motility assays were 
used to verify flagellin expression by S. maltophilia, L. pneumophila, and S. enterica serovar Typhimurium. 
WT-PAK and the PAK/fliC¯ flagellin-deficient strain were used as positive and negative controls, respectively. 
Bars represent mean ± S.E. colony diameters (mm) as a functional assay for motility (n = 5). *, increased motility 
compared with the PAK/fliC¯ strain at p < 0.05. (B) To establish the time profile for MUC1-ED shedding, A549 
cells (2.0 ×  105 cells/well) cultured in 24-well plates were incubated for increasing times with fixed inocula 
of either WT-PAK or the PAK/fiC¯ mutant (1.0 ×  107 CFUs/well). At each time point, MUC1-ED levels in 
cell culture supernatants were measured by ELISA and normalized to total A549 cell protein. (C) A549 cells 
(2.0 ×  105 cells/well) in 24-well plates were incubated for 24 h at 37 °C with 1.0 ×  107 CFUs/well of the indicated 
bacterial strains, 100 ng/well of Pa LPS, 10 µg/well of  Pam3Cys-Ser-(Lys)4, 10 µg/well of CpG ODN 1826, 10 ng/
well of Pa or STm flagellins, 10 ng/well of Pa rFlaA or rFla flagellins, or the PBS vehicle control. MUC1-ED 
levels in cell culture supernatants were measured by ELISA and normalized to total A549 cell protein. (D) A549 
cells (2.0 ×  105 cells/well) cultured in 24-well plates were incubated for 24 h at 37 °C with increasing CFUs/
well of WT-PAK or the PAK/fliC¯ flagellin-deficient strain. MUC1-ED levels in cell culture supernatants were 
measured by ELISA and normalized to total cell protein. (B–D) Bars and data points represent mean ± S.E. 
values (n = 3 or 5). (A, C) Open circles represent individual values. *, increased MUC1-ED levels compared 
with (A, B, D) PAK/fliC¯ or (C) the PBS control at p < 0.05. **, decreased MUC1-ED levels provoked by the 
PAK/fliC¯ flagellin-deficient strain compared with WT-PAK at p < 0.05. (E) WT-PAK (lanes 1, 3, 5) or the PAK/
fliC¯ mutant strain (lanes 2, 4, 6) were co-cultured for 24 h with A549 cells, the supernatants collected, and 
centrifuged at 5,000 xg for 10 min to collect the bacteria. The bacteria were lysed and equal protein aliquots 
(10 µg) of the lysates processed for MUC1-ED immunoblotting to detect Pa:MUC1-ED complexes. Molecular 
weights in kDa are indicated on the left. The arrow indicates the > 250 kDa MUC1-ED band of interest. IB, 
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Figure 4.  Pa-derived flagellin is present in the BALF of Pa-infected VAP patients. (A) Pa FlaA and FlaB 
flagellin levels in BALF from Pa-infected patients (n = 13) were quantified by ELISA and normalized to total 
BALF protein. (B) Box and whisker plots of the data in (A). *, increased MUC1-ED levels compared with 
FlaA-negative or FlaB-negative BALF. n.s., not significant. (C) Increasing CFUs of FlaA-expressing PAK or 
FlaB-expressing PA01 bacteria were cultured in LB medium or DMEM containing 10% FBS in the presence 
or absence of A549 cells. The bacteria were lysed and the lysates processed for FlaA or FlaB levels by ELISA. 
Standard curves were calculated by linear regression. (D) Pa lung burden was calculated using the flagellin 
levels in (A) with interpolation from the standard curves in (C). Bars represent mean ± S.E. values (n = 3). Open 
circles represent individual values. (E) MUC1-ED levels in BALFs that cultured positive for FlaA-expressing Pa 
(n = 7) were compared with MUC1-ED levels in BALFs that cultured positive for FlaB-expressing Pa (n = 6). Bars 
represent mean ± S.E. MUC1-ED levels normalized total BALF protein. Open circles represent individual values. 
(F) BALF Pa FlaA and FlaB levels in (A) were correlated with BALF MUC1-ED levels (Fig. 2A) and analyzed by 
linear regression. The results are representative of 3 independent experiments.
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excluding coinfection with two Pa strains expressing the same flagellin type. To establish how many Pa CFUs 
a given flagellin level reflects, PAK and PA01 bacteria were cultured in either bacterial medium or eukaryotic 
tissue culture medium, in the presence or absence of A549 cells, to simulate Pa lung infection more closely, 
in vivo. Increasing inocula of PAK and PA01 bacteria were lysed and the lysates processed for FlaA or FlaB 
ELISA (Fig. 4C). Using these FlaA and FlaB standard curves, and given the comparable levels of flagellin found 
in laboratory and clinical Pa  strains28, a crude estimate of the Pa lung burden for each patient was calculated. 
Using the FlaA/FlaB standard curves with PAK/PA01 grown in Luria–Bertani (LB) broth, a mean lung burden 
of 5.52 ×  108 CFU/mg (range, 2.82 ×  108 to 8.24 ×  108 CFU/mg) was estimated for the 13 Pa-infected VAP patients 
(Fig. 4D, blue bars). Using the FlaA/FlaB standard curves with PAK/PA01 grown in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% fetal bovine serum (FBS) in the presence of A549 cells, a mean lung burden 
of 10.72 ×  108 CFU/mg (range, 6.03 ×  108 to 15.04 ×  108 CFU/mg) was estimated for the Pa-infected VAP patients 
(Fig. 4D, red bars). Using the FlaA/FlaB standard curves with PAK/PA01 grown in DMEM plus 10% FBS in the 
absence of A549 cells, a mean lung burden of 14.11 ×  108 CFU/mg (range, 7.08 ×  108 to 20.77 ×  108 CFU/mg) was 
estimated for the Pa-infected VAP patients (Fig. 4D, green bars). It is conceivable that the lower estimate for 
mean lung burden generated with Pa cultured with vs. without A549 cells reflects the presence of cell-associated 
and/or shed, Pa-targeting MUC1-ED. Next, we compared MUC1-ED levels in the BALFs that cultured positive 
for FlaA-expressing Pa (n = 7) to MUC1-ED levels in BALFs that cultured positive for FlaB-expressing Pa (n = 6) 
(Fig. 4E). No difference was detected between the two groups. Finally, each BALF FlaA or FlaB level was cor-
related with the BALF MUC1-ED level in the same patient for all 61 VAP patients (Fig. 4F). Linear regression 
analysis revealed a significant correlation between FlaA/FlaB levels and shed MUC1-ED levels (FlaA/MUC1-
ED,  r2 = 0.8187, p = 4.38 ×  10−23; FlaB/MUC1-ED,  r2 = 0.7754, p = 8.64 ×  10−26). However, as with MUC1-ED levels 
(Supplemental Fig. 1), FlaA and FlaB levels in BALF of Pa-infected VAP patients (n = 11) did not correlate with 
APACHE II scores (Supplemental Fig. 3). Therefore, Pa-derived FlaA and FlaB flagellins can be detected in VAP 
patient BALFs, and the levels of these two flagellins each positively correlates with MUC1-ED shedding.
Human recombinant MUC1‑ED as a flagellin‑targeting decoy receptor and promoter of phago‑
cytosis. Flagellin contributes to Pa pathogenesis through increased motility, biofilm formation, adhesion 
to and invasion of airway epithelia, and inflammation through activation of EC-expressed TLR5, downstream 
interleukin (IL)-8 production, and pulmonary leukostasis, predominantly with polymorphonuclear leukocytes 
(PMNs)29–34. In a mouse model of Pa pneumonia, endogenous murine MUC1-ED in BALF diminishes Pa motil-
ity and adhesion to airway  ECs22. Further, using metabolic inhibitors of protein glycosylation and a nonglyco-
sylated, E. coli-derived human rMUC1-ED, we demonstrated that the decoy receptor function of MUC1-ED 
resides within its protein backbone and not its N- or O-linked  carbohydrates22. To further validate the utility of 
human rMUC1-ED as a Pa flagellin-targeting intervention, we used immunogold transmission electron micros-
copy (EM) to establish its binding to the intact Pa flagellum. Gold-labeled anti-mouse IgG secondary antibody 
immunolocalized to the Pa flagellar filament following incubation of the bacteria with human rMUC1-ED and 
mouse anti-MUC1-ED antibody (Fig. 5A, panel i), but not to bacteria incubated with rMUC1-ED and a nonim-
mune mouse IgG control (Fig. 5A, panel ii). Next, we tested human rMUC1-ED for its ability to inhibit flagellin-
dependent Pa motility. Human rMUC1-ED dose-dependently inhibited Pa motility by up to 81.4%, compared 
with the simultaneous PBS vehicle control. (Fig. 5B). In a Pa biofilm assay where the bacteria were incubated 
with increasing amounts of rMUC1-ED in plastic microwells, rMUC1-ED reduced Pa biofilm formation by 
up to 90.5% (Fig. 5C). In a bacterial adhesion assay where Pa were cultured with A549 cells in the presence of 
increasing amounts of rMUC1-ED, Pa adhesion to the ECs was dose-dependently diminished by up to 78.4% 
(Fig. 5D). When these same ECs were incubated with Pa in the presence of the same escalating concentrations of 
rMUC1-ED, IL-8 levels in the cell culture supernatants were reduced by up to 80.5% (Fig. 5E). Finally, in a PMN 
opsonophagocytosis assay where green fluorescent protein (GFP)-expressing Pa were incubated with primary 
human PMNs in the presence of increasing amounts of rMUC1-ED, intracellular levels of GFP-Pa were dose-
dependently elevated up to 3.87-fold compared with the simultaneous PBS control (Fig. 5F). However, human 
rMUC1-ED at 100 µM displayed no effect on the growth of flagellin-expressing Pa, compared with the PBS con-
trol (Fig. 5G). Thus, human rMUC1-ED, at concentrations comparable to those of MUC1-ED found in the BALF 
of Pa-infected patients (Fig. 2A,B) exhibits robust, flagellin-targeting decoy receptor function and enhances the 
PMN phagocytic response to Pa, without inhibiting bacterial replication.
Discussion
In the current study, 21.3% of mechanically ventilated patients were infected with Pa. Pa is the second most 
common microorganism isolated in U.S. hospital-acquired lung infections with 90,000 cases per  year35. In a 
prospective study of mechanically ventilated ICU patients across 56 sites in 11 countries, the incidence of Pa 
pneumonia ranged from 13.5% to 19.4%36. In a review of 24 studies, Pa was the most frequent isolate from ICU 
VAP patients, accounting for 24.4% of all microorganisms  isolated12. Of the 13 Pa-positive patients in our study, 
8 (61.5%) were identified in a chronic ventilator Comprehensive Pulmonary Rehabilitation Unit and 5 (38.5%) 
in an acute tertiary care medical ICU (Table 1). The increased incidence of Pa-positive patients in the chronic vs. 
acute ICU setting likely represents longer duration of intubation in the chronic  ICU7. In fact, Pa lung infection 
was associated with a reduction in the number of ventilator-free days (8.2 ± 11.3 days) compared with Pa-negative 
patients (18.7 ± 10.0 days).
The current study supports Pa-derived flagellin as a ligand for the MUC1-ED, and suggests that flagellin 
engagement of the cell-associated MUC1-ED provokes MUC1-ED shedding in the airways of VAP patients. Using 
an in vivo experimental murine model to explore lung responsiveness to Pa, we have established flagellin-driven 
MUC1-ED shedding from the airway EC surface as a novel, Pa-selective host response to lung  infection22. More 
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specifically, purified Pa-derived flagellin dose-dependently increased MUC1-ED shedding from the murine 
airway epithelium into the brochoalveolar compartment. In the current study, BALF levels of the two Pa flagellin 
types, FlaA and FlaB, each could be tightly correlated with BALF levels of shed MUC1-ED in the same patient. 
Pa flagellin levels predicted MUC1-ED levels in a concentration-dependent manner. In these same patients, 
we found a greater than 6.0-fold increase in the mean ± S.E. MUC1-ED level in the BALF of Pa-infected VAP 
patients (4.01 ± 0.19 µg/mg BALF protein) compared with that observed in Pa-negative patients (0.66 ± 0.05 µg/
mg) (Fig. 2A,B). No differences in BALF MUC1-ED levels were seen between patients infected with microorgan-
isms other than Pa (0.71 ± 0.05 µg/mg) and those who were culture-negative (0.52 ± 0.08 µg/mg), indicating that 
the elevation of MUC1-ED levels is specific for Pa lung infection. Although S. maltophilia increased MUC1-ED 
shedding in vitro (Fig. 3C), whether BALF MUC1-ED levels are increased in patients with S. maltophilia lung 
infections is unknown. Of note, 100% of VAP patients who were Pa-positive had MUC1-ED levels ≥ 2.87 µg/mg 
BALF protein (range, 2.87 to 5.34 µg/mg), whereas all patients who were infected with other microorganisms 
or culture-negative had MUC1-ED levels ≤ 1.55 µg/mg (range, 0.05 to 1.55 µg/mg). Based on these data, 2.0 µg 
MUC1-ED/mg BALF protein provides a reliable diagnostic cut-off value to discriminate between Pa-infected and 
non-Pa-infected patients. Elevated BALF MUC1-ED levels may offer a predictive biomarker for Pa lung infection 
in VAP patients. The MUC1-ED ELISA is more rapid, less labor intensive, and less expensive than conventional 
bacterial cultures. However, the MUC1-ED ELISA identifies only Pa, and unlike bacterial cultures, does not 
provide antibiotic sensitivities. Further studies are required to establish whether elevated BALF MUC1-ED levels 
might also result from S. maltophilia lung infections.
In the mouse, Pa-stimulated MUC1-ED desialylation and shedding is a NEU1 sialidase-dependent  process22. 
While NEU1 has historically been studied in context of its indispensable role in glycan  catabolism37, far less 
is known about its role in the host response to septic processes, including Pa lung infection. We previously 
established NEU1 as the predominant sialidase expressed in human airway epithelial  cells23. Silencing of NEU1 
expression reduces total human lung airway EC sialidase activity by more than 70%. We detected NEU1 immu-
nostaining in the superficial epithelium along the entire human airway, including the brush  border23. This NEU1 
expression pattern closely correlates with that known for MUC1 in these same  tissues38,39. The MUC1-ED isolated 
from BALF of Pa-infected patients was desialylated (Fig. 2D). We have previously demonstrated that increased 
levels of soluble, desialylated MUC1-ED offer an indirect but specific measure of NEU1 catalytic  activity21,22. We 
found that after siRNA-induced NEU1 silencing, MUC1-ED desialylation and shedding from Pa flagellin-exposed 
airway ECs is  nonexistent21. Similarly, in a previous study, we found that NEU1-selective sialidase pharmacologic 
inhibition dramatically reduces MUC1-ED shedding in Pa-challenged  mice22. These combined data indicate that 
NEU1 catalytic activity is increased in the lungs of Pa-infected patients. In previous coimmunoprecipitation 
and PNA lectin blotting studies, flagellin stimulation increased NEU1 association with and desialylation of the 
MUC1-ED22. NEU1-driven MUC1-ED desialylation unmasked not only cryptic binding sites for Pa flagellin, 
dramatically increasing Pa adhesion to lung ECs, but also the MUC1-ED glycine-serine protease recognition 
site, permitting its proteolytic cleavage and release from the airway EC  surface22. With these results in mind, it is 
not surprising that desialylated MUC1-ED could not be detected in the BALF of patients who were Pa culture-
negative or infected with microorganisms other than Pa (Fig. 2D, lanes 1–4).
Pa flagellin constitutes an important virulence factor through bacterial motility, adhesion to and invasion of 
host epithelia, and inflammatory gene expression via engagement of host  TLR529–32. Flagellin-dependent motility 
and adhesion to ECs are both prerequisites for Pa biofilm  formation33 and flagellin is a target of opsonophago-
cytosis by host  PMNs34. Host factor(s) disrupting one or more flagellin-driven processes would be predicted to 
protect against Pa pathogenesis. At MUC1-ED concentrations similar to those found in the BALF of Pa-infected 
patients, the Pa flagellin-targeting, E. coli-expressed human rMUC1-ED decoy receptor reduced Pa motility, 
adhesion to alveolar ECs and biofilm formation, as well as IL-8 production, and enhanced neutrophil-medi-
ated Pa phagocytosis. Whether MUC1-ED bound to Pa flagellin functions as an authentic opsonin is unclear. 
Human rMUC1-ED exerted no measurable bacteriostatic or bactericidal activity. Through its ability to impair 
flagellin-driven Pa motility, MUC1-ED may interfere with Pa penetration of the mucus  blanket40, invasion of 
the  epithelium23, movement through the paracellular pathway into subepithelial  tissues41, and/or Pa resistance to 
Figure 5.  Human rMUC1-ED exhibits flagellin-targeting decoy receptor function, and enhances the PMN 
phagocytic response. (A) PAK was incubated for 1 h at 4 °C with 25 µM of human rMUC1-ED. The bacteria 
were washed with PBS, pH 7.4 and incubated for 1 h at 4 °C with mouse anti-MUC1-ED antibody (panel i) or 
nonimmune mouse IgG control (panel ii), each at 1:5,000 dilution, followed by 1 h at 4 °C with gold-labeled 
goat anti-mouse IgG secondary antibody at 1:10,000 dilution. Bacterial flagella were examined by transmission 
immunoelectron microscopy. Each section was photographed at 44,000X. Scale bar, 25 nm. (B, C) The indicated 
concentrations of human rMUC1-ED or the PBS vehicle control were incubated with PAK, and the bacteria 
were washed and assayed for (B) motility and (C) biofilm formation. (D, E) The indicated concentrations of 
human rMUC1-ED or the PBS vehicle control were incubated with PAK, and (D) the bacteria were assayed for 
adhesion to A549 cells and (E) cell culture supernatants were assayed for IL-8 levels by ELISA. (F) The indicated 
concentrations of human rMUC1-ED or the PBS vehicle control were incubated with WT-PAK or the PAK/fliC¯ 
flagellin-deficient strain and the bacteria were assayed for phagocytosis by PMNs. Bars represent mean ± S.E. 
values (n = 3). Open circles represent individual values. **, significantly decreased Pa motility, biofilm, adhesion, 
or IL-8 levels compared with the PBS control, or phagocytosis of PAK/fliC¯ compared with WT-PAK, at p < 0.05. 
*, significantly increased WT-PAK phagocytosis compared with the PBS control at p < 0.05. (G) PAK were 
cultured with 100 µM of human rMUC1-ED or the PBS vehicle, cultured over time in LB medium, and assayed 
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mucociliary  clearance42. Inhibition of flagellin-dependent Pa adhesion to host airway epithelia likely decreases Pa 
colonization and invasion of subepithelial tissues. Disruption of the MUC1-ED-Pa flagellin receptor-ligand inter-
action blocks MUC1-driven downstream intracellular  signaling43, biosynthesis of proinflammatory cytokines/
chemokines44,45, pulmonary  leukostasis22, and neutrophil recruitment to the bronchoalveolar  compartment46. 
On the other hand, NEU1-mediated release of sialic acid residues from the highly sialylated MUC1-ED substrate 
may facilitate their incorporation into sialic acid-rich Pa  biofilms33 and/or dampen complement  activation47, 
thereby contributing to Pa pathogenesis.
In conclusion, MUC1-ED and Pa-derived flagellin were detected in the BALF of Pa-infected VAP patients 
at dramatically elevated levels compared with those found in Pa-negative patient BALF. Extending the ex vivo 
studies to an in vitro model of Pa infection, stimulation of human alveolar ECs with either Pa or S. maltophilia, 
but not other recognized airway pathogens, increased MUC1-ED levels in cell culture supernatants and purified 
rFlaA and rFlaB flagellins recapitulated the effect of intact Pa bacteria. E. coli-expressed, human rMUC1-ED 
dose-dependently inhibited Pa motility, adhesion to alveolar epithelia, biofilm formation, and IL-8 production, 
while at the same time, enhanced neutrophil-mediated Pa phagocytosis, without influencing bacterial growth. 
The current studies expand our previous observation of a flagellin-provoked, NEU1-mediated generation of a 
MUC1-ED decoy receptor in a mouse model of Pa  pneumonia22 to human in vivo pathophysiology. Measure-
ment of MUC1-ED and flagellin BALF levels offer a rapid, reliable means to identify ventilated patients with Pa 
pneumonia that might serve as a guide for empiric antibiotic therapy. Of note, the mechanism of action of most 
conventional antibiotics requires bacterial replication and cell wall  remodeling13. It is conceivable that human 
rMUC1-ED, which itself does not alter bacterial replication, might be combined with antibiotics for synergistic 
therapy against MDR Pa.
Methods
Ethics statement. This study was conducted in accordance with the Declaration of Helsinki and other local 
statutes or regulations protecting subjects in biomedical research, and was approved by the Institutional Review 
Boards of the University of Maryland Baltimore (protocol numbers HP-00059183 and HP-00083805). Informed 
consent was obtained from all participants.
Study setting and design. This study was conducted using BALF collected from VAP patients at the Uni-
versity of Maryland Medical Center (Baltimore, MD). VAP patients were admitted either to the 29-bed Medical 
Intensive Care Unit (MICU) or the 9-bed Critical Care Resuscitation Unit (CCRU) of the University Teaching 
Hospital, or received prolonged mechanical ventilation in the 14-bed Comprehensive Pulmonary Rehabilitation 
Unit (CPRU) of the long-term acute care University Specialty Hospital. Patient data were collected as part of 
routine hospital standard of care, including age, race, gender, body mass index (BMI), ICU location, ventilator-
free days, antibiotics administered, chest x-ray, APACHE II score, and microbiology culture results. Bacterial 
identification of surveillance cultures was done at the University of Maryland Medical Center Clinical Microbi-
ology Laboratory following standard laboratory procedures using the Vitek MS for bacterial identification and 
Vitek-2 system for antimicrobial susceptibilities (Biomerieux, Marcy l’Etoile, France) and interpreted according 
to Clinical and Laboratory Standards Institute (CLSI)  criteria48. Clinical diagnosis of VAP was based on findings 
of a new pulmonary infiltrate by chest x-ray in the setting of fever, purulent sputum, leukocytosis, and dimin-
ished  oxygenation1.
Bronchoalveolar lavage and tracheal aspiration. BAL was performed on VAP patients undergoing 
standard of care diagnostic bronchoscopy. Briefly, after conscious sedation with fentanyl and midazolam, and 
local anesthesia with 2% lidocaine, the bronchoscope was wedged in a 3rd or 4th order bronchus, after which 
125 ml of sterile pyrogen-free 0.9% NaCl was injected in 25-ml aliquots. The BALF was retrieved, pooled, filtered 
through sterile gauze, centrifuged at 450 xg to remove cells, and the supernatant concentrated 25-fold by ultrafil-
tration and stored until use at − 80 °C. Tracheal aspiration was performed using a 12 French siliconized polyvinyl 
chloride tracheal aspiration probe (Embramed, Brazil) as  described49.
Bacteria. Pa strains PA01, GFP-PA01, PAK, and PAK/fliC¯, Pa clinical strains isolated from pneumo-
nia patients, L. pneumophila, S. pneumoniae, H. influenzae, S. aureus, and K. pneumoniae were previously 
 described22,23,50–52. S. maltophilia strain 810–2 was obtained from the American Type Culture Collection (Manas-
sas, VA). All bacteria were cultured at 37 °C in LB medium (10 mg/ml tryptone, 5.0 mg/ml yeast extract, 10 mg/
ml NaCl) (Thermo Fisher Scientific, Waltham, MA), and quantified spectrophotometrically at  A600. In selected 
experiments, Pa strains PA01 and PAK were cultured at 37 °C in DMEM containing 10% FBS (Hyclone Labora-
tories, Logan, UT) in the presence or absence of confluent monolayers of A549 human alveolar ECs (American 
Type Culture Collection).
Purification of Pa and STm flagellins. An overnight culture of PA01 was centrifuged at 5000×g for 
30 min, resuspended in Krebs–Ringer buffer, and incubated for 1 h at 37 °C. The bacteria were collected by cen-
trifugation and the supernatant was filtered through a 0.22 μm pore membrane and the filtrate boiled for 20 min. 
The filtrate was concentrated by centrifugal ultrafiltration, adjusted to pH 6.0, and flagellin purified by sequential 
ion exchange chromatography using Macro-Prep High S and Macro-Prep High Q resins (Bio-Rad). Flagellin 
was purified from STm strain CVD1925 as  described53,54. Pa and STm flagellins were incubated with polymyxin 
B-agarose (Thermo Fisher Scientific) to remove LPS, after which less than 0.1 endotoxin units/µg of protein was 
detected by the Limulus amebocyte lysate assay.
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Expression and purification Pa rFlaA and rFlaB flagellins. The DNA sequences of the FlaA (Gen-
Bank accession no. CP020659.1) and FlaB (GenBank accession no. AE004091.2) genes from PAK and PA01, 
respectively, were codon optimized for expression in Escherichia coli (GenScript, Piscataway, NJ), cloned into 
pUC57 and pJET1.2, respectively, and the plasmids transformed into E. coli NEB 5-alpha competent cells (New 
England BioLabs, Ipswich, MA). The FlaA and FlaB genes were amplified by PCR, cloned into pTrcHis-TOPO 
(Thermo Fisher Scientific), and expressed in E. coli BL21 competent cells (New England Biolabs) for production 
and purification of 6XHis-tagged rFlaA and rFlaB  proteins54. The 6X-His-FlaA and FlaB proteins were purified 
on a nickel-nitrilotriacetic acid affinity column (Thermo Fisher Scientific), their identities verified by immuno-
blotting with anti-FlaA and anti-FlaB antibodies, and purities confirmed by a single Coomassie blue-stained 
protein band following SDS-PAGE.
MUC1‑ED shedding by human airway epithelia, in vitro. A549 cells (2.0 ×  105 cells/well) in 24-well 
plates were incubated for increasing times at 37 °C with 1.0 ×  107 CFUs/well of WT-PAK or the PAK/fliC¯ flagel-
lin-deficient strain, or were incubated for 24 h with increasing inocula WT-PAK or PAK/fliC¯. In other experi-
ments, A549 cells were incubated for 24 h with 1.0 ×  107 CFUs/well of Pa strains PA01, WT-PAK, or PAK/fliC¯, 
Pa clinical strains isolated from pneumonia patients, S. maltophilia, L. pneumophila, S. pneumoniae, H. influen-
zae, S. aureus, or K. pneumoniae. In still other experiments, A549 cells were incubated with 100 ng/well of Pa 
LPS (Sigma-Aldrich, St. Louis, MO), 10 µg/well of  Pam3Cys-Ser-(Lys)4 (Sigma), 10 µg/well of CpG ODN 1826 
(InvivoGen, San Diego, CA), 10 ng/well of Pa or STm flagellins, 10 ng/well of Pa rFlaA or rFla flagellins, or the 
PBS vehicle control. MUC1-ED levels in cell culture supernatants were measured by ELISA and normalized to 
total cell protein.
ELISA. BALF and A549 cell culture supernatants in 96-well ELISA plates were incubated for 2 h at 22 °C 
with mouse anti-human MUC1-ED antibody, mouse anti-rFlaA or anti-FlaB antibodies, or mouse anti-human 
IL-8 antibody (Thermo Fisher Scientific). The wells were incubated for 2 h at 22 °C with 200 µg/ml of HRP-
conjugated goat anti-mouse IgG secondary antibody (KPL, Gaithersburg, MD), and bound antibodies detected 
with tetramethylbenzidine substrate (KPL) at  A450. Standard curves were generated using purified rMUC1-ED, 
rFlaA, rFlaB, and rIL-8 proteins.
MUC1‑ED immunoblotting. Equal protein aliquots of BALFs were resolved by SDS-PAGE. In order to 
adequately visualize the > 250 kDa MUC1-ED protein, discontinuous gel electrophoresis was performed under 
reducing conditions in 3% stacking/5% separating acrylamide gels containing 25 mM Tris–HCl, 190 mM gly-
cine, 0.1% SDS, pH 8.3 until the 150 kDa prestained protein molecular weight marker reached the bottom of the 
gel. The resolved proteins were transferred to polyvinylidene fluoride (PVDF) membranes (Bio-Rad, Hercules, 
CA) and the membranes probed with rabbit anti-mouse MUC1-ED antibody, followed by HRP-conjugated goat 
anti-rabbit IgG secondary antibody and enhanced chemiluminescence reagents (Thermo Fisher Scientific), as 
 described22.
PNA lectin blotting of desialylated MUC1‑ED. Equal protein aliquots of BALF were incubated with 
PNA immobilized on agarose beads (Vector Laboratories, Burlingame, CA) to selectively enrich for PNA-bind-
ing proteins and the PNA-bound proteins resolved by SDS-PAGE as described above. The resolved proteins 
were transferred to PVDF membranes, and the membranes processed for MUC1-ED immunoblotting as above. 
Asialofetuin (1.0 µg) was used as a positive control for PNA-binding proteins whereas fetuin (1.0 µg) was used 
as a negative control.
Bacterial motility assay. Bacteria in mid-log phase  (A600 = 0.5), were resuspended in LB medium, stab-
inoculated into 0.3% LB agar plates, incubated overnight, and colony diameters measured as an indicator of 
bacterial motility, as  described22. In other experiments, PAK were preincubated with increasing concentrations 
rMUC1-ED, washed, resuspended in LB medium, and analyzed for motility.
Detection of Pa:MUC1‑ED complexes. A549 cells (2.0 ×  105 cells/well) were cultured in DMEM con-
taining 10% FBS in 24-well plates. The cells were incubated for 24 h at 37 °C with 1.0 ×  108 CFUs/well of WT-PAK 
or the PAK/fliC¯ flagellin-deficient strain. The bacteria were collected by centrifugation of culture supernatants 
at 5,000 xg for 10 min, washed 3 times with PBS, pH 7.4, and lysed. Equal protein aliquots (10 µg) of the lysates 
were processed for MUC1-ED immunoblotting as above.
Expression and purification of human rMUC1‑ED. Human MUC1-ED incorporating flanking NcoI 
and EcoRI restriction sites was amplified by PCR from a full-length MUC1-pcDNA3  plasmid55 and the ampli-
cons subcloned into the pBAD/6X-His plasmid (Thermo Fisher Scientific). The plasmid was transformed into E. 
coli NEB 5-alpha competent cells (New England Biolabs), the cells were cultured to mid-log phase  (A600 = 0.5), 
induced for 3 h with 0.01% arabinose, and lysed by sonication. The 6X-His epitope-tagged human rMUC1-ED 
was purified on a nickel-nitrilotriacetic acid affinity column, its identity verified by immunoblotting with anti-
human MUC1-ED antibody, and purity confirmed by a single Coomassie blue-stained protein band following 
SDS-PAGE.
Immunogold EM. Immunogold electron microscopy using a Tecnai T12 transmission electron microscope 
(Thermo Fisher Scientific) to detect rMUC1-ED binding to Pa flagellin was performed as previously  described56.
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Pa biofilm assay. Overnight cultures of PAK in LB medium were adjusted to  A600 = 0.1 in M9 medium, 
incubated for 48 h at 37 °C in 96-well plates with increasing concentrations rMUC1-ED, washed with deionized 
water, stained with 0.1% crystal violet for 10 min at 22 °C, and washed with deionized water. The crystal violet 
was solubilized with 30% acetic acid for 10 min at 22 °C and  A595 measured.
Pa adhesion to human alveolar ECs. A549 cells were cultured in DMEM containing 10% FBS. The 
cells were infected with adenovirus encoding NEU1 at a multiplicity of infection of 100 in 24-well plates as 
 described21–23, incubated for 40 min at 37 °C with PA01 (2.0 ×  107 CFUs/well) in the presence of increasing con-
centrations of rMUC1-ED or the PBS vehicle control, and washed 3 times with PBS, pH 7.4. Bound bacteria were 
released with 0.05% trypsin, and CFUs quantified on LB agar plates.
Pa opsonophagocytosis assay. An overnight culture of GFP-PA01 was inoculated into 10 ml of fresh 
LB medium and grown to mid-log phase  (A600 = 0.5) in LB medium. The bacteria were centrifuged, washed, 
and diluted in PBS to obtain the desired number of bacteria. GFP-PA01 were incubated for 10 min at 22 °C 
with increasing concentrations of rMUC1-ED or the PBS vehicle control as  described57. Approximately 1.0 ×  106 
human PMNs for each reaction were added to the bacteria in a 96 well microtiter plate, incubated for 2 h at 
37 °C, aliquots added to LB agar, and the viable colonies quantified after overnight incubation.
Statistical analysis. For comparison of patient clinical and demographic parameters, values were expressed 
as mean ± S.D. All other values were expressed as mean ± S.E. The two-tailed Student’s t test, analysis of variance 
followed by Tukey’s post hoc analysis, and linear regression were performed using the Microsoft Excel Analysis 
ToolPak add-in. Statistical significance was set at p < 0.05. Power and sample size analyses were performed as 
 described58,59 using our prior pilot study of BALF MUC1-ED levels in Pa-positive (n = 4) vs. Pa-negative (n = 11) 
 patients21. The null hypothesis was defined as the mean BALF MUC1-ED level of Pa-positive patients being 
equal to the mean BALF MUC1-ED level of Pa-negative patients. Sample sizes for the Pa-positive group (n = 13) 
and Pa-negative group (n = 48) in the current study achieve 100% power to detect a difference of 3.33 µg MUC1-
ED/mg BALF protein between the null hypothesis and the alternative hypothesis that the mean BALF MUC1-
ED level of Pa-positive patients in the pilot study is 3.87 µg/mg BALF protein and the mean BALF MUC1-ED 
level of Pa-negative patients in the pilot study is 0.54 µg/mg BALF protein, with group standard deviations of 
0.50 and 0.31, respectively, and with a significance level (alpha) of 0.05 using a two-sided two-sample t-test.
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